BTK inhibitors have become a cornerstone of CLL therapy, as B cell receptor (BCR) signaling is a key dependency of CLL cells that is required to sustain prosurvival signals from the microenvironment19. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.